Clinical Trials
48 trialsEfficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC
Hunan Province Tumor Hospital
Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy
The First Affiliated Hospital of Xinxiang Medical College
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
Samsung Medical Center
Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer
Qingdao Central Hospital
Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer
Qingdao Central Hospital
BEVERLY
National Cancer Institute, Naples
MiST
University of Leicester
Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.
The Second Affiliated Hospital of Shandong First Medical University
Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma
Fujian Cancer Hospital
SPBPDC
Qianfoshan Hospital
Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC
Sichuan Cancer Hospital and Research Institute
A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion
The First Affiliated Hospital of Zhengzhou University
AvaTa
National Cancer Center, Korea
Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer
The Netherlands Cancer Institute
A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC
Shanghai Chest Hospital
Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC
Guangdong Association of Clinical Trials
ATTRACT
Second Affiliated Hospital of Nanchang University
Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma
Sichuan Cancer Hospital and Research Institute
The Effects of Preoperative Bevacizumab on Perioperative Complications
Second Affiliated Hospital, School of Medicine, Zhejiang University
BELLA
Guangdong Association of Clinical Trials
OWBLM
Second Affiliated Hospital of Nanchang University
Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer
Sun Yat-sen University
Clinical Trial in Chinese Healthy Volunteers of GB222
Genor Biopharma Co., Ltd.
OWONBNSCLCLM
Second Affiliated Hospital of Nanchang University
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors
The University of Hong Kong
Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene
Sun Yat-sen University
To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer
Sinocelltech Ltd.
Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC
Samsung Medical Center
BRILLIANT
National Taiwan University Hospital
A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer
Luye Pharma Group Ltd.
Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease
Beijing Hospital
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.
Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients
Grupo de Investigación y Divulgación Oncológica
Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance
Tongji University
BevMar
Karolinska University Hospital
Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer
Sun Yat-sen University
Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion
Tang-Du Hospital
Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC
Zhejiang University
VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
Huazhong University of Science and Technology
Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer
Sichuan Cancer Hospital and Research Institute
Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer
St. John Providence Health System
Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
The Cooper Health System